Related Experiment Video

Updated: Sep 29, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Statin treatment following coronary artery stenting and one-year survival

Albert Schömig1, Julinda Mehilli, Heidrun Holle

  • 1Deutsches Herzzentrum and 1. Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany. aschoemig@dhm.mhn.de

Journal of the American College of Cardiology
|September 13, 2002
PubMed

Insights

Statin therapy after coronary artery stenting significantly improves one-year survival in patients with coronary artery disease. This treatment reduces the risk of death by approximately 50% in stenting patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Coronary artery stenting is a common procedure for symptomatic coronary artery disease (CAD).
  • Statin therapy is proven to improve survival in conservatively managed CAD patients.
  • The benefit of statins in patients undergoing coronary stenting was previously unknown.

Purpose of the Study:

  • To evaluate the impact of post-procedure statin therapy on one-year survival.
  • To determine if statins offer survival benefits to patients after coronary artery stenting.

Main Methods:

  • A cohort of 4,520 patients under 80 years old undergoing coronary stenting was analyzed.
  • One-year mortality was compared between 3,585 patients receiving statins and 935 not receiving statins post-procedure.

Main Results:

  • Patients receiving statins had a one-year mortality rate of 2.6% versus 5.6% in non-statin users.
  • Statin therapy was associated with a 54% unadjusted reduction in one-year mortality (OR 0.46).
  • Adjusted analysis showed a 49% reduction in mortality risk (OR 0.51) with statins, consistent across subgroups.

Conclusions:

  • Statin therapy administered after coronary artery stenting improves patient survival.
  • The survival benefit of statins is independent of patient characteristics at the time of intervention.
Abstract

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...